Intech Biopharm Ltd (6461) - Net Assets
Based on the latest financial reports, Intech Biopharm Ltd (6461) has net assets worth NT$1.10 Billion TWD (≈ $34.69 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.35 Billion ≈ $74.07 Million USD) and total liabilities (NT$1.25 Billion ≈ $39.38 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 6461 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.10 Billion |
| % of Total Assets | 46.83% |
| Annual Growth Rate | -2.56% |
| 5-Year Change | -17.69% |
| 10-Year Change | N/A |
| Growth Volatility | 20.04 |
Intech Biopharm Ltd - Net Assets Trend (2017–2025)
This chart illustrates how Intech Biopharm Ltd's net assets have evolved over time, based on quarterly financial data. See 6461 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Intech Biopharm Ltd (2017–2025)
The table below shows the annual net assets of Intech Biopharm Ltd from 2017 to 2025. For live valuation and market cap data, see market cap of Intech Biopharm Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.10 Billion ≈ $34.69 Million |
+35.21% |
| 2024-12-31 | NT$814.28 Million ≈ $25.65 Million |
-30.28% |
| 2023-12-31 | NT$1.17 Billion ≈ $36.79 Million |
+13.20% |
| 2022-12-31 | NT$1.03 Billion ≈ $32.50 Million |
-22.87% |
| 2021-12-31 | NT$1.34 Billion ≈ $42.14 Million |
+0.67% |
| 2020-12-31 | NT$1.33 Billion ≈ $41.86 Million |
-15.31% |
| 2019-12-31 | NT$1.57 Billion ≈ $49.43 Million |
+5.44% |
| 2018-12-31 | NT$1.49 Billion ≈ $46.88 Million |
+9.80% |
| 2017-12-31 | NT$1.36 Billion ≈ $42.70 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Intech Biopharm Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60341300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$2.06 Billion | 187.16% |
| Total Equity | NT$1.10 Billion | 100.00% |
Intech Biopharm Ltd Competitors by Market Cap
The table below lists competitors of Intech Biopharm Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XAC Automation
TWO:5490
|
$85.99 Million |
|
Thai Plaspac Public Company Limited
BK:TPAC
|
$86.01 Million |
|
Biomea Fusion Inc
NASDAQ:BMEA
|
$86.04 Million |
|
Oroco Resource Corp
V:OCO
|
$86.06 Million |
|
Golden Bridge Electech Inc
TW:6133
|
$85.89 Million |
|
Forsys Metals Corp.
TO:FSY
|
$85.86 Million |
|
Pc Iletisim ve Medya Hizmetleri Sanayi Ticaret AS
IS:PCILT
|
$85.79 Million |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
$85.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intech Biopharm Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 814,279,000 to 1,100,983,000, a change of 286,704,000 (35.2%).
- Net loss of 389,032,000 reduced equity.
- New share issuances of 433,912,000 increased equity.
- Other factors increased equity by 241,824,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-389.03 Million | -35.33% |
| Share Issuances | NT$433.91 Million | +39.41% |
| Other Changes | NT$241.82 Million | +21.96% |
| Total Change | NT$- | 35.21% |
Book Value vs Market Value Analysis
This analysis compares Intech Biopharm Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.80x to 2.48x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$19.08 | NT$15.30 | x |
| 2018-12-31 | NT$18.33 | NT$15.30 | x |
| 2019-12-31 | NT$15.16 | NT$15.30 | x |
| 2020-12-31 | NT$12.84 | NT$15.30 | x |
| 2021-12-31 | NT$12.81 | NT$15.30 | x |
| 2022-12-31 | NT$8.88 | NT$15.30 | x |
| 2023-12-31 | NT$9.69 | NT$15.30 | x |
| 2024-12-31 | NT$5.81 | NT$15.30 | x |
| 2025-12-31 | NT$6.17 | NT$15.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intech Biopharm Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.33%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -361.80%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 2.14x
- Recent ROE (-35.33%) is below the historical average (-26.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -17.66% | -1440.96% | 0.01x | 1.65x | NT$-374.84 Million |
| 2018 | -14.92% | -1288.59% | 0.01x | 1.69x | NT$-370.88 Million |
| 2019 | -19.85% | -1866.60% | 0.01x | 1.66x | NT$-468.33 Million |
| 2020 | -18.84% | -1186.25% | 0.01x | 1.97x | NT$-383.25 Million |
| 2021 | -22.56% | -775.74% | 0.01x | 1.94x | NT$-435.52 Million |
| 2022 | -31.78% | -1386.55% | 0.01x | 2.47x | NT$-431.05 Million |
| 2023 | -28.94% | -1307.64% | 0.01x | 2.32x | NT$-454.77 Million |
| 2024 | -45.22% | -925.63% | 0.02x | 2.94x | NT$-449.63 Million |
| 2025 | -35.33% | -361.80% | 0.05x | 2.14x | NT$-499.13 Million |
Industry Comparison
This section compares Intech Biopharm Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,605,275,000
- Average return on equity (ROE) among peers: 6.79%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intech Biopharm Ltd (6461) | NT$1.10 Billion | -17.66% | 1.14x | $85.97 Million |
| Apex Biotechnology Corp (1733) | $1.75 Billion | 11.53% | 0.52x | $92.11 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.32 Billion | 9.26% | 0.78x | $190.85 Million |
| Panion & BF Biotech Inc (1760) | $1.93 Billion | 5.40% | 0.53x | $161.80 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.50 Billion | 21.29% | 0.26x | $85.54 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $969.06 Million | 16.12% | 0.26x | $101.71 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $31.95 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $44.44 Million |
| Medigen Biotechnology (3176) | $3.46 Billion | -15.61% | 0.30x | $146.59 Million |
| Sagittarius Life Science (3205) | $588.38 Million | -12.60% | 0.26x | $112.36 Million |
| Genovate Biotechnology Co Ltd (4130) | $2.25 Billion | 1.74% | 0.18x | $112.45 Million |
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide… Read more